TY - JOUR AU - Hal, Melinda AU - Hal, Viktor AU - Vécsei, László AU - Balog, Anna AU - Majláth, Zsófia AU - Tajti, János AU - Ertsey, Csaba AU - Bozsik, György AU - Zsombók, Terézia Ibolya AU - Purebl, György TI - Personality traits and psychological complaints under patients suffering from headaches JF - IDEGGYOGYASZATI SZEMLE / CLINICAL NEUROSCIENCE J2 - IDEGGYOGY SZEMLE VL - 76 PY - 2023 IS - 11-12 SP - 385 EP - 393 PG - 9 SN - 0019-1442 DO - 10.18071/isz.76.0385 UR - https://m2.mtmt.hu/api/publication/34417253 ID - 34417253 N1 - Learning Institute, Mathias Corvinus Collegium, Budapest, Hungary Department of Applied Psychology, Semmelweis University, Budapest, Hungary Department of Psychiatry, Szent Rókus Hospital Baja, Baja, Hungary Department of Neurology, Albert Szent-Györgyi Clinical Center, University of Szeged, Szeged, Hungary ELKH-SZTE, Neuroscience Research Group, Szeged, Hungary Department of Neurology, Semmelweis University, Budapest, Hungary Institute of Behavioural Sciences, Semmelweis University, Budapest, Hungary Export Date: 9 January 2024 CODEN: IDSZA Correspondence Address: Hal, M.; Learning Institute, Hungary; email: hal.melinda@mcc.hu AB - Background and purpose – Although headaches are often comorbid with psychological symptoms, the underlying psychological processes, e.g. the role of personality dimensions as headache determinants remains unclear. Studies found associations between headaches and various personality traits; according to the Big Five model of personality, persons suffering from headaches exhibit a higher rate in neuroticism, while a lower rate in extraversion, openness to experiences and positive emotions. This is the first study to clarify the associations among duration, intensity, and frequency of headaches and personality dimensions. Through this study we could get into the personality dimensions in the background of pain experience and that which personality dimensions bear a part in the behaviour of the persons, who suffered from headache, but do not seek treatment through this complaint. Methods – Treated (Group1) and untreated (Group2) headache patients and healthy controls (Group3) were investigated (total of 360 participants). The main headache components of intensity, duration, and frequency were used as dependent variables with personality dimensions in the Big Five concept investigated by the NEO-PI-R Personality Inventory. Results – Employing multiple regression analysis, facets of personality described 14.7% of headache intensity, 10.9 % of duration, and 18.7 % of frequency variance. Group1 and Group2 reached significantly higher values on the dimension of anxiety, depression, and vulnerability to stress than Group3. Group1 showed a significantly higher value on trust personality dimension than Group3 and Group2. Group3 exhibited a significantly higher value in the trust dimension than Group2. Concerning vulnerability to stress, the highest value was yielded by the “treated and suffering from headaches” group and there was a significant difference also with the “untreated and suffering from headaches” group and with the control group. In this dimension, the “untreated and suffering from headaches” group’s point value was significantly higher than the control group’s (p<0.01, U=-4.501). Conclusion – Our study demonstrates that the three headache components are not independent from personality traits, and personality traits may interact with treatment seeking behavior even in the presence of significant headache complaints. The role of the personality traits are significant in the intensity, duration and frequency of headaches. LA - English DB - MTMT ER - TY - CHAP AU - Majláth, Zsófia AU - Szalárdy, Levente AU - Zádori, Dénes AU - Klivényi, Péter AU - Fülöp, Ferenc AU - Toldi, József AU - Vécsei, László ED - Kostrzewa, Richard M. TI - Neuroprotection by Kynurenine Metabolites T2 - Handbook of Neurotoxicity PB - Springer Nature Switzerland CY - Cham SN - 9783031150807 PY - 2023 SP - 1067 EP - 1080 PG - 14 DO - 10.1007/978-3-031-15080-7_165 UR - https://m2.mtmt.hu/api/publication/33665496 ID - 33665496 LA - English DB - MTMT ER - TY - JOUR AU - Petrovics-Balog, Anna AU - Majláth, Zsófia AU - Lukács, Melinda AU - Holczer, Adrienn AU - Must, Anita AU - Tajti, János AU - Vécsei, László TI - The effect of psychiatric comorbidities and stress-coping strategies on perceived quality of life in migraine. JF - IDEGGYOGYASZATI SZEMLE / CLINICAL NEUROSCIENCE J2 - IDEGGYOGY SZEMLE VL - 72 PY - 2019 IS - 11-12 SP - 397 EP - 404 PG - 8 SN - 0019-1442 DO - 10.18071/isz.72.0397 UR - https://m2.mtmt.hu/api/publication/31040417 ID - 31040417 N1 - Összes idézések száma a WoS-ban: 0 AB - Migraine is one of the most disabling primary headache conditions. We aimed to detect hidden symptoms of anxiety and depression and to survey stress-coping mechanisms and related quality of life in a large migraine population without any known psychiatric comorbidity.123 migraine patients (MG) and 66 healthy subjects (HC) completed the Beck Depression Inventory-II (BDI-II), the State and Trait Anxiety Inventory (S-STAI and T-STAI), the Stress and Coping Inventory (SCI) and the 36-Item Short Form Health Survey (SF-36).MG patients reached significantly higher scores on the BDI-II and the T-STAI yielding previously undetected anxiety and depression symptoms. Significant differences were present on the SCI: higher stress scores and lower coping levels suggested impaired stress-coping strategies in migraine. MG patients achieved significantly lower scores on most of SF-36 subscales indicating lower perceived quality of life. Significant correlations were found between BDI-II, T-STAI, SCI scores and subscales of the SF-36.Unrecognized symptoms of anxiety and depression, as well as less effective stress-coping strategies might be related to the lower perceived quality of life in migraine. The screening of these symptoms might lead to more focused and efficient therapeutic strategies. Addressing stress management techniques could improve quality of life on the long-term. LA - English DB - MTMT ER - TY - JOUR AU - Majláth, Zsófia AU - Annus, Ádám AU - Vécsei, László TI - Kynurenine system and multiple sclerosis, pathomechanism and drug targets with an emphasis on laquinimod JF - CURRENT DRUG TARGETS J2 - CURR DRUG TARGETS VL - 19 PY - 2018 IS - 7 SP - 805 EP - 814 PG - 10 SN - 1389-4501 DO - 10.2174/1389450117666161223125417 UR - https://m2.mtmt.hu/api/publication/3371556 ID - 3371556 N1 - University of Szeged, Department of Neurology, Semmelweis u. 6, Szeged, H-6725, Hungary MTA-SZTE Neuroscience Research Group of the Hungarian Academy of Sciences and University of Szeged, Semmelweis u. 6, Szeged, H-6725, Hungary Cited By :13 Export Date: 11 September 2023 CODEN: CDTUA Correspondence Address: Vécsei, L.; University of Szeged, Semmelweis u. 6, Hungary; email: vecsei.laszlo@med.u-szeged.hu Chemicals/CAS: 3 hydroxyanthranilic acid, 548-93-6; advanced glycation end product receptor, 198785-73-8, 247590-69-8; benserazide, 14919-77-8, 322-35-0; carbidopa, 28860-95-9, 38821-49-7; cytochrome P450 3A4, 329736-03-0; gamma interferon, 82115-62-6; gelatinase B, 146480-36-6; interleukin 12, 138415-13-1; kynurenic acid, 492-27-3; kynurenine, 16055-80-4, 343-65-7; laquinimod, 248281-84-7, 248282-07-7; melatonin, 73-31-4; nicotinamide adenine dinucleotide, 53-84-9; quinidine, 56-54-2; quinolinic acid, 89-00-9; roquinimex, 84088-42-6; serotonin, 50-67-9; toll like receptor 4, 203811-83-0; tryptophan 2,3 dioxygenase, 9014-51-1; Kynurenine; laquinimod; Neuroprotective Agents; Quinolones Tradenames: linomide Funding details: Magyar Tudományos Akadémia, MTA, KTIA-13-NAP-A-II/17, KTIA-13-NAP-A-III/9 Funding text 1: This work was supported by the the MTA-SZTE Neuroscience Research Group of the Hungarian Academy of Sciences and the University of Szeged and by the projects entitled GINOP-2.3.2-15-2016-00034 and the Hungarian Brain Research Programme (NAP, Grant No. KTIA-13-NAP-A-III/9. and KTIA-13-NAP-A-II/17.). AB - Multiple sclerosis is a common chronic, disabling autoimmune neurological disease affecting mainly young adults. In its pathomechanism, neurodegenerative and acute inflammatory characteristics are both involved. Disease-modifying therapies aim to reduce relapse-rate and slow down the deterioration in neurological functions. The currently available therapies fail to exert neuroprotective effects and most of them are associated with potentially toxic side-effects, therefore, ongoing research aims to develop novel drug candidates to cover these therapeutic gaps. The kynurenine pathway has been implicated in both the physiological processes of the central nervous system and in the pathomechanism of several neurological disorders as well. Alterations of the kynurenine pathway metabolites have been detected in multiple sclerosis and a number of potential therapeutic targets related to this metabolic route have been already identified. Laquinimod is a quinoline carboxamide showing structural similarities with kynurenic acid, which proved to have beneficial effects on reduction of brain atrophy and disability progression. The kynurenine pathway is therefore a promising target for the development of future drugs for the treatment of autoimmune diseases such as multiple sclerosis. LA - English DB - MTMT ER - TY - PAT AU - Dékány, Imre AU - Krizbai, István AU - Majláth, Zsófia AU - Toldi, József AU - Varga, Noémi AU - Vécsei, László TI - Sustained release nanocomposite, a process for producing the same and use thereof PY - 2017 UR - https://m2.mtmt.hu/api/publication/31890251 ID - 31890251 LA - English DB - MTMT ER - TY - CHAP AU - Tajti, János AU - Szok, Délia AU - Vécsei, László AU - Vörös, Erika Sarolta AU - Gárdián, Gabriella AU - Majláth, Zsófia ED - Vécsei, László ED - Szok, Délia TI - Neurológiai betegségek klinikai vonatkozásai T2 - Neurológia a betegágynál PB - Medicina Könyvkiadó CY - Budapest SN - 9789632266329 PY - 2017 SP - 77 EP - 146 PG - 70 UR - https://m2.mtmt.hu/api/publication/3277014 ID - 3277014 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Majláth, Zsófia AU - Obál, Izabella AU - Vécsei, László TI - Treatment possibilities for psychosis in parkinson's disease with an emphasis on the newly approved drug: pimavanserin JF - CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS J2 - CNS NEUROL DISORD-DR VL - 16 PY - 2017 IS - 3 SP - 234 EP - 243 PG - 10 SN - 1871-5273 DO - 10.2174/1871527315666161006104347 UR - https://m2.mtmt.hu/api/publication/3253312 ID - 3253312 AB - Parkinson's disease (PD) is a progressive neurodegenerative disorder with prominent motor and non-motor symptoms. Psychosis develops in over 40% of PD patients and it is one of the most distressing symptoms for patients and caregivers alike. Until recently, atypical antipsychotics, clozapine and quetiapine were used to treat psychotic symptoms, but treatment was associated with substantial concerns for side-effects of clozapine and unfounded efficacy for quetiapine. Extensive research has shown that the antipsychotic effect of these drugs could be attributed to serotonin 2a receptor (5-HT2A) triggered mechanisms. A selective 5-HT2A inverse agonist, pimavanserin, has been developed, investigated and has gained approval in April 2016 in the US for the treatment of hallucinations and delusions in PD. In this review we primarily focus on psychosis in PD, the current treatment possibilities and the new, emerging therapy, pimavanserin, a selective 5-HT2A inverse agonist. All articles were reviewed in this topic and indexed in PubMed with keywords: Parkinson's disease psychosis, serotonin 2a receptor inverse agonist, clozapine, quetiapine, pimavanserin. LA - English DB - MTMT ER - TY - JOUR AU - Rajda, Cecília AU - Pukoli, Dániel AU - Bende, Zsuzsanna AU - Majláth, Zsófia AU - Vécsei, László TI - Excitotoxins, mitochondrial and redox disturbances in multiple sclerosis JF - INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES J2 - INT J MOL SCI VL - 18 PY - 2017 IS - 2 PG - 28 SN - 1661-6596 DO - 10.3390/ijms18020353 UR - https://m2.mtmt.hu/api/publication/3192890 ID - 3192890 N1 - Funding Agency and Grant Number: MTA-SZTE Neuroscience Research Group of the Hungarian Academy of Sciences; University of Szeged, the Hungarian Brain Research Program (NAP) [KTIA-13-NAP-A-II/18, GINOP-2.3.2-15-2016-00034] Funding text: This work was supported by the MTA-SZTE Neuroscience Research Group of the Hungarian Academy of Sciences and the University of Szeged, the Hungarian Brain Research Program (NAP, Grant No. KTIA-13-NAP-A-II/18) and GINOP-2.3.2-15-2016-00034. We wish to thank Jennifer Tusz for editing the English of this manuscript. AB - Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS). There is increasing evidence that MS is not only characterized by immune mediated inflammatory reactions, but also by neurodegenerative processes. There is cumulating evidence that neurodegenerative processes, for example mitochondrial dysfunction, oxidative stress, and glutamate (Glu) excitotoxicity, seem to play an important role in the pathogenesis of MS. The alteration of mitochondrial homeostasis leads to the formation of excitotoxins and redox disturbances. Mitochondrial dysfunction (energy disposal failure, apoptosis, etc.), redox disturbances (oxidative stress and enhanced reactive oxygen and nitrogen species production), and excitotoxicity (Glu mediated toxicity) may play an important role in the progression of the disease, causing axonal and neuronal damage. This review focuses on the mechanisms of mitochondrial dysfunction (including mitochondrial DNA (mtDNA) defects and mitochondrial structural/functional changes), oxidative stress (including reactive oxygen and nitric species), and excitotoxicity that are involved in MS and also discusses the potential targets and tools for therapeutic approaches in the future. © 2017 by the authors; licensee MDPI, Basel, Switzerland. LA - English DB - MTMT ER - TY - PAT AU - Dékány, Imre AU - Krizbai, I AU - Majláth, Zsófia AU - Toldi, J AU - Varga, N AU - Vécsei, László TI - Hatóanyagoknak a központi idegrendszerben történő szabályozott leadására alkalmas nanokompozit, eljárás annak előállítására és alkalmazása CY - Country:10001(1) PY - 2017 UR - https://m2.mtmt.hu/api/publication/2974963 ID - 2974963 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Tajti, János AU - Szok, Délia AU - Majláth, Zsófia AU - Tuka, Bernadett AU - Csáti, Anett AU - Vécsei, László TI - Corrigendum to “Migraine and neuropeptides” [Neuropeptides (2015) 19–30] JF - NEUROPEPTIDES J2 - NEUROPEPTIDES VL - 60 PY - 2016 SP - 91 EP - 91 PG - 1 SN - 0143-4179 DO - 10.1016/j.npep.2016.10.001 UR - https://m2.mtmt.hu/api/publication/3163235 ID - 3163235 N1 - Department of Neurology, University of Szeged, Semmelweis u. 6, Szeged, H-6725, Hungary MTA – SZTE Neuroscience Research Group, Semmelweis u. 6, Szeged, H-6725, Hungary Export Date: 21 January 2024 CODEN: NRPPD Correspondence Address: Tajti, J.; Department of Neurology, Semmelweis u. 6, Hungary; email: tajti.janos@med.u-szeged.hu Funding details: KTIA_13_NAP-A-III/9 Funding details: Seventh Framework Programme, FP7, 602633 Funding details: Magyar Tudományos Akadémia, MTA Funding details: Szegedi Tudományegyetem, SZTE Funding text 1: This work was supported by the project TÁMOP-4.2.2.A-11/1/KONV-2012-0052, by the Hungarian Brain Research Programme (NAP, Grant No. KTIA_13_NAP-A-III/9 ), by EUROHEADPAIN ( FP7 -Health 2013-Innovation; Grant No. 602633 ) and by the MTA – SZTE Neuroscience Research Group of the Hungarian Academy of Sciences and the University of Szeged , Szeged, Hungary. LA - English DB - MTMT ER -